GWS
CBAY

Glassman Wealth Services’s Cymabay Therapeutics CBAY Stock Holding History

Glassman Wealth Services’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$11 – 2078
2023
Q2 		$11 Hold
1
– – ﹤0.01% 1902
2023
Q1 		$9 Hold
1
– – ﹤0.01% 1891
2022
Q4 		$6 Hold
1
– – ﹤0.01% 1908
2022
Q3 		$0 Hold
1
– – ﹤0.01% 2065
2022
Q2 		$0 Buy
+1
New +$2 ﹤0.01% 2089
2020
Q4 		– Sell
-535
Closed -$4K – 1563
2020
Q3 		$4K Buy
535
+300
+128% +$1.6K ﹤0.01% 863
2020
Q2 		$1K Buy
+235
New +$678 ﹤0.01% 1157

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Glassman Wealth Services's CBAY Position: Q3 2023 in Review

Glassman Wealth Services sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 1 share — an estimated $11 sold.

Glassman Wealth Services first reported a position in CBAY in Q2 2020 and held it in 7 quarters. The position peaked at $4K in Q3 2020. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

  • Glassman Wealth Services reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 1 Cymabay Therapeutics share in Q3 2023, an estimated $11.
  • Glassman Wealth Services first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 7 quarters.
  • Glassman Wealth Services's Cymabay Therapeutics position peaked at $4K in Q3 2020.
  • 189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Glassman Wealth Services's 13F filing for Q3 2023, filed 14 Nov 2023.